Recently, the novel coronavirus disease 2019 , has attracted the attention of scientists where it has a high mortality rate among older adults and individuals suffering from chronic diseases, such as chronic kidney diseases (CKD). It is important to elucidate molecular mechanisms by which COVID-19 affects the kidneys and accordingly develop proper nutritional and pharmacological strategies. Although numerous studies have recently recommended several approaches for the management of COVID-19 in CKD, its impact on patients with renal diseases remains the biggest challenge worldwide. In this paper, we review the most recent evidence regarding causality, potential nutritional supplements, therapeutic options, and management of COVID-19 infection in vulnerable individuals and patients with CKD. To date, there is no effective treatment for COVID-19-induced kidney dysfunction, and current treatments are yet limited to anti-inflammatory (e.g. ibuprofen) and anti-viral medications (e.g. Remdesivir, and Chloroquine/Hydroxychloroquine) that may increase the chance of treatment. In conclusion, the knowledge about kidney damage in COVID-19 is very limited, and this review improves our ability to introduce novel approaches for future clinical trials for this contiguous disease.

The essential oil of Syzygium aromaticum (clove EO) and its major ingredients, eugenol, possess many biological activities such as antibacterial, antifungal, and antioxidant properties. Therefore, they have been widely used in traditional and contemporary medicine. In this study, the ingredients of clove EO were identified using GC‐MS analysis. The antibacterial and leishmanicidal activities of the total essential oil and eugenol were also investigated. Eugenol (65.41%), trans‐caryophyllene (12.6%), eugenol acetate (9.85%), caryophyllene oxide (3.00%), and α‐humulene (1.73%) were identified as five major components of clove EO. Additionally, the obtained IC50s of clove EO, 177.66, 300.53, 362.94, and 248.08 μg/mL, against Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae, respectively, were lower than those of eugenol with IC50s of 320.80, 692.91, 591.82, and 445.87 μg/mL. However, this difference was not significant, except against E coli. Also, clove EO and eugenol showed proper leishmanicidal effects on promastigotes of Leishmania tropica (180.24 and 233.52 μg/mL) and Leishmania major (654.76 and 517.14 μg/mL). Furthermore, there was no significant statistical difference between the anti‐Leishmania effect of EO and eugenol. Clove EO and eugenol showed proper antibacterial and leishmanicidal activities. However, the use of clove EO is preferable than eugenol because of the lower cost and straightforward preparation process.

No abstract

FeOOH nanoparticles are commonly synthesized at very high temperature and pressure that makes the process energy consuming and non-economic. Recently, novel approaches were developed for the fabrication of these particles at room temperature. But, the main problem with these methods is that the prepared structures are aggregates of ultra-small nanoparticles where no intact separate nanoparticles are formed. In this study, for the first time, secretory compounds from Chlorella vulgaris cells were employed for the controlled synthesis of FeOOH nanoparticles at room atmosphere. Obtained particles were found to be goethite (α-FeO(OH)) crystals. Controlled synthesis of FeOOH nanoparticles resulted in uniform spherical nanoparticles ranging from 8 to 17 nm in diameter with 12.8 nm mean particle size. Fourier-transform infrared and elemental analyses were indicated that controlled synthesized nanoparticles have not functionalized with secretory compounds of C. vulgaris, and these compounds just played a controlling role over the synthesis reaction.

No abstract